跳至主要内容
临床试验/IRCT20230618058508N1
IRCT20230618058508N1招募中3 期

Evaluation of the role of oral whey protein with Terminalia Chebula(an Iranian Medicine product) on mild to moderate skin lesion of psoriasis – A Triple-blind randomized controlled trial.

Tehran University of Medical Sciences0 个研究点目标入组 90 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
All

入选标准

  • Age between 18 and 60
  • Less than 10% of skin involvement
  • Suffering from controlled plaque psoriasis (Unchanged damages in terms of severity and extent in the last 2 months)
  • Not using psoralen in the last 28 days and not receiving UVB in the last 30 days
  • No kidney disease or kidney stones
  • Not being during pregnancy and breastfeeding
  • Not participating in any study in the last month
  • Consent to participate in the study

排除标准

  • Suffering from other types of psoriasis, such as pustular, erythrodermic, palmoplantar, psoriatic arthritis
  • Allergy to milk and other dairy product
  • Suffering from kidney stones and kidney disease
  • Using drugs aggravating psoriasis, such as beta-blockers, non-steroidal anti-inflammatory drugs, calcium channel blockers, interleukins, and lithium
  • suffering from uncontrolled cardiovascular, respiratory, hematologic or urinary diseases

研究者

相似试验